Title: A Phase 3, Randomized, Open-label Study of PF-06821497 (Mevrometostat) in Combination With Enzalutamide Compared With Enzalutamide or Docetaxel in Participants With Metastatic Castration Resistant Prostate Cancer Previously Treated With Abiraterone Acetate (MEVPRO-1)
- Principal Investigator: Dr. Martin Schoen
- Study Coordinators: Carley Browning
The purpose of this study is to learn about the investigational medicine called PH-06821497 (mevrometostat) in men with mCRPC who were previously treated with abiraterone acetate for prostate cancer.
This study is to evaluate whether the addition of EZH2 (enhancer of zeste homologue-2) inhibition to enzalutamide can reverse anti-androgen resistance, thereby in increasing the duration of clinical benefit of enzalutamide in participants who have previously been treated with abiraterone. This Phase 3 randomized study (C2321014) is designed to demonstrate the PT-06821497 plus enzalutamide provides superior clinical benefit compared to physician’s choice of therapy (enzalutamide or docetaxel) in participants with mCRPC 9 metastatic castration resistant prostate cancer.
The study is administered by VREF and funded by Pfizer through the Department of Defense (DOD).
Find Out More
To learn more about MEVPRO-1 and how you can join contact our research office at (314) 289-7690.
If you are a veteran receiving care through the VA St. Louis Health Care System and believe you may be eligible for this study, please speak with your Physician. For general information about our research, please visit our main Clinical Trials page or contact us directly.